August 18, 2017 6:55 AM ET

Personal Products

Company Overview of XYMOGEN, Inc.

Company Overview

XYMOGEN, Inc., doing business as Atlantic Pro-Nutrients, Inc., produces dietary supplements. It offers products in the areas of lifestyle, women's health, men's health, cytokine balance support, adrenal support, cardiovascular health, blood sugar support, body composition, immune health, sports nutrition, antioxidants, bone health, detoxification, essential fatty acids, and probiotics. The company offers its products through licensed healthcare practitioners in the United States and internationally. XYMOGEN, Inc. was incorporated in 1990 and is based in Orlando, Florida.

6900 Kingspointe Parkway

Orlando, FL 32819

United States

Founded in 1990





Key Executives for XYMOGEN, Inc.

Co-Founder, Chief Executive Officer and Member of Board of Advisors
Chief Operating Officer
Senior Vice President
Chairman of The Medical Board of Advisors and Chief Neuroscience Officer
Director of Educational Development
Compensation as of Fiscal Year 2017.

XYMOGEN, Inc. Key Developments

XYMOGEN® Introduces its Patented and Exclusive MonoPure™ Line of Omega-3 EPA + DHA Products

XYMOGEN® has announced the introduction of its patented and exclusive MonoPure™ line of omega-3 EPA + DHA products. What makes MonoPure™ so different from other omega-3 EPA + DHA products is that it delivers an easy to digest highly concentrated omega-3 fish oil, which when studied clinically was shown to be three times more absorbable than ethyl ester (EE) fish oil. MonoPure™ also offers consumers the ability to get more bioavailable doses of omega-3 EPA + DHA in smaller softgels than with the EE form or reduce the number of softgels to be taken per day. This easy-to-swallow, easy-to-digest and highly absorbable omega-3 supplement means patients are more likely to take their practitioner-recommended dose and achieve the health benefits they are looking for. The introduction of MonoPure™ into the market means more than just providing patients the convenience of swallowing fewer and in some cases smaller capsules. It also means patients' bodies can access the essential fatty acids in a much more efficient way, including patients with malabsorption conditions or compromised digestive health. Patients suffering from these types of conditions can, for example, include the elderly, celiac or cystic fibrosis patients, those with gallstones or chronic pancreatitis among others. The complete line of MonoPure™ formulas includes Omega MonoPure 650 EC made of 650 mg of MaxSimil® fish oil omega-3 concentrate providing 300 mg of EPA, and 130 mg of DHA per softgel; Omega MonoPure MD EC made of 500 mg of MaxSimil® fish oil omega-3 concentrate providing 230 mg of EPA, 100 mg of DHA, and 50 mg of Arthricor® olive extract per softgel; and Omega MonoPure 1300 EC made of 1.3 g of MaxSimil® fish oil omega-3 concentrate providing 600 mg of EPA and 260 mg of DHA per softgel.

XYMOGEN to Manufacture and Supply the Oral Vitamin and Mineral Preparations

XYMOGEN announce that it has been chosen by Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to manufacture and supply the oral vitamin and mineral preparations that will be tested in the second Trial to Assess Chelation Therapy (TACT2). Chelation is a process by which a medication, such as edetate disodium, can 'grab' toxic metals like lead or cadmium which are present in most individuals' bodies and allow for their removal in the urine. Standard chelation therapy is typically given in conjunction with oral vitamins and minerals, which XYMOGEN will provide for the study. TACT2 is funded by the National Center for Complementary and Integrative Health (NCCIH), the National Heart, Lung and Blood Institute, as well as the National Institute of Diabetes and Digestive and Kidney Diseases, of the National Institutes of Health (NIH). TACT2 will examine the use of intravenous chelation therapy in combination with the oral vitamins supplied by XYMOGEN to determine if either chelation or oral vitamins and minerals will reduce cardiovascular events in patients with diabetes and a history or a heart attack.

Similar Private Companies By Industry

Company Name Region
220 Laboratories, Inc. United States
29 Luxury Goods, Inc. United States
3000BC LLC United States
310 Nutrition, LLC United States
400 Beverly, Inc. United States

Recent Private Companies Transactions

Private Placement
May 24, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact XYMOGEN, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at